Can bosentan reverse lung artery thickening? small study investigates
NCT ID NCT00595049
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether bosentan (Tracleer) can reduce the thickness of lung artery walls in people with a type of high blood pressure in the lungs (pulmonary arterial hypertension, or PAH). Eleven adults with PAH took bosentan for 6 months. Researchers measured artery wall thickness and how well small blood vessels in the lungs responded to natural chemicals. The goal was to see if the drug could improve artery structure and function.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERTENSION, PULMONARY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Royal Prince Alfred Hospital
Camperdown, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Which drug is best for pulmonary hypertensive crisis? new trial aims to find out
- AI stethoscope aims to spot silent heart and lung disease
- Could a hormone supplement ease lung pressure in COPD?
- Fat in the heart: new clues for PAH?
- Can a traditional chinese herb pill help Lung-Heart patients breathe easier?
- Could a natural hormone help COPD patients breathe easier?